FDA: Control of Nitrosamine Impurities
The FDA published the second revision to the industry guidance on "Control of Nitrosamine Impurities in Human Drugs".
Update compared to the guidance of 2021:
- New section that describes nitrosamine drug substance-related impurities (NDSRIs) - NDSRIs are a class of nitrosamines sharing structural similarity to the API. NDSRIs can be generated during the manufacturing process or during storage of a finished drug.
- Potential root causes of NDSRIs
- Mitigation strategies to prevent or reduce the presence of NDSRIs
The guidance describes two general structural classes of nitrosamine impurities:
- Small-molecule nitrosamine impurities (they do not share structural similarity to the API)
- NDSRIs that share structural similarity to the API and are generally unique to each API
NDRSIs are also addressed in the guidance “Recommended Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities (NDSRIs)“ (August 2023).
Weblink to acceptable limits: FDA/CDER Nitrosamine Impurity Acceptable Intake Limits
Source:
PDA/FDA Joint Regulatory Conference 2024
Tina Kiang, Ph.D., Director, Division of Regulations and Guidance, FDA/OPQ/OPPQ
FDA: Control of Nitrosamine Contamination in Pharmaceuticals for Human Use
Meet the GMP Compliance Adviser
The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business.
The demo access is non-binding and ends automatically.
You may also be interested in the following articles:
